Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (4): 473-478.

Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药

张新然¹, 张弋¹, 高慧儿¹, 强兆艳², 李咏梅^3*

1.天津市第一中心医院药学部,天津 300192;
2.天津医科大学基础医学院药理学系,天津 300070;
3.天津医科大学基础医学院病原生物学系,天津 300070

收稿日期:2019-06-17 修回日期:2019-11-04 出版日期:2020-04-05 发布日期:2020-04-06
通讯作者: *liym@tmu.edu.cn
基金资助:
国家自然科学基金青年科学基金(81800165)

Shc3 over-expression inhibits apoptosis of HCC cells and is involved in drug resistance

ZHANG Xin-ran¹, ZHANG Yi¹, GAO Hui-er¹, QIANG Zhao-yan², LI Yong-mei^3*

1. Department of Pharmacy, Tianjin First Central Hospital, Tianjin 300192;
2. Department of Pharmacology, Basic Medicine College, Tianjin Medical University, Tianjin 300070;
3. Department of Pathogen Biology, Basic Medicine College, Tianjin Medical University, Tianjin 300070, China

Received:2019-06-17 Revised:2019-11-04 Online:2020-04-05 Published:2020-04-06
Contact: *liym@tmu.edu.cn

摘要/Abstract

摘要： 目的探讨Shc3对人肝细胞癌HCC细胞凋亡及耐药机制。方法选取稳定下调Shc3的人肝细胞癌系HCCLM3和HepG2细胞及其对照组scramble细胞,稳定上调Huh7和HepG2细胞及其对照组pCDH细胞。Western blot检测Shc3、MEK、p-MEK、ERK和p-ERK蛋白表达;real-time PCR检测Shc3 mRNA表达;凋亡实验检测细胞凋亡;CCK-8法检测细胞增殖。结果成功验证Shc3降表达及过表达细胞系;与scramble组比较,Shc3降表达组细胞MEK/ERK通路激活程度明显降低(P＜0.05),细胞凋亡比例增加(P＜0.05);与pCDH组比较,Shc3表达上调增加细胞对索拉菲尼耐受性(P＜0.05),并且MEK/ERK通路激活程度明显增强(P＜0.05)。结论 Shc3可通过干扰HCC细胞凋亡,激活MEK/ERK通路,增加HCC细胞对索拉菲尼的耐药性,本研究结果为靶向Shc3治疗肝细胞癌提供了理论依据和实验室基础。

关键词: 人肝细胞癌, Shc3, 细胞凋亡, 细胞耐药

Abstract: Objective To investigate the apoptosis and drug resistance mechanism of Src homolog and collagen homolog 3 (Shc3) in human hepatocellular carcinoma (HCC). Methods Human hepatocellular carcinoma cell lines HCCLM3 and HepG2 with stable Shc3 downregulation and their scramble cell control groups were selected, Huh7 and HepG2 cells with stable Shc3 up-regulation and their pCDH control groups were selected. Protein expression levels of Shc3,MEK,p-MEK,ERK and p-ERK were determined by Western blot analysis. The mRNA level of Shc3 were determined by real-time PCR. Apoptotic experiment was used to observe cell apoptosis. CCK-8 assays were used to observe cell proliferation. Results Shc3 down-regulation and up-regulation cell lines were proved. Compared with scramble cells, Shc3 down-regulation significantly decreased activity of MEK/ERK pathway (P＜0.05), promoted cell apoptosis significantly (P＜0.05). Compared with pCDH cells, Shc3 up-regulation increased cell tolerance to sorafenib (P＜0.05), Moreover, significantly enhanced activity of MEK/ERK pathway (P＜0.05). Conclusions Shc3 may increase the resistance of HCC cells to sorafenib by interfering with apoptosis of HCC cells and activating MEK/ERK pathway. The results of this study provide theoretical basis and laboratory basis for targeting at Shc3 in the treatment of hepatocellular carcinoma.

Key words: human hepatocellular carcinoma, Shc3, cell apoptosis, cell resistance

中图分类号:

R739.41

张新然, 张弋, 高慧儿, 强兆艳, 李咏梅. Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药[J]. 基础医学与临床, 2020, 40(4): 473-478.

ZHANG Xin-ran, ZHANG Yi, GAO Hui-er, QIANG Zhao-yan, LI Yong-mei. Shc3 over-expression inhibits apoptosis of HCC cells and is involved in drug resistance[J]. Basic & Clinical Medicine, 2020, 40(4): 473-478.

参考文献

[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66:115-132.
[2]Llovet JM, Burroughs A, Bruix J. Hepatocellular carcino-ma[J]. Lancet, 2003, 362: 1907-1917.
[3]Liu Y, Zhang XR, Yang BC, et al. Demethylation-induced overexpression of Shc3 interacts with MVP and activates MEK/ERK independent of c-Raf[J]. Cancer Res, 2018, 78:2219-2233.
[4]Miyake I, Ohira M, Nakagawara A, et al. Distinct role of ShcC docking protein in the differentiation of neuroblas-toma[J]. Oncogene, 2009, 28: 662-673.
[5]Sun JX, Shi J, Li N, et al. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma[J]. Cancer Biol Med, 2016, 13:452-458.
[6]Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma[J]. Hepatology, 1998, 27:951-958。
[7]张新然,强兆艳,庄昊,等. GDF15表达下调促进人胶质母细胞瘤细胞系U87MG增殖[J]. 基础医学与临床,2017,37:1557-1561.
[8]De Falco V, Guarino V, Malorni L, et al. RAI (ShcC/N-Shc)-dependent reemitment of GAB1 to RET oncoproteins potentiates PI3-K signaling in thyroid tumors[J]. Oncogene, 2005, 24: 6303-6313.
[9]Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activa-tion of Ras and Jak/Stat pathways in human HCC[J]. Gastroenterology, 2006, 130: 1117-1128.
[10]Yang QS, Jiang LP, He CY, et al. Up-Regulation of microRNA-133a inhibits the MEK/ERK signaling pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in esophageal cancer in vivo and in vitro[J]. J Cell Biochem, 2017, 118: 2625-2634.
[11]Raoul JL, Adhoute X, Gilabert M, et al. How to assess the efficacy or failure of targeted therapy: deciding when to stop sorafenib in hepatocellular carcinoma[J]. World J Hepatol, 2016, 8: 1541-1546.
[12]Mazzoccoli G, Miele L, Oben J, et al. Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib[J]. Curr Drug Targets, 2016, 17:783-799.
[13]Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851-11858.

[1]	王婷婷, 魏欢, 杨永丽, 周贤, 胡阳. 三七皂苷Rg1对阿尔茨海默症大鼠的神经系统的保护作用[J]. 基础医学与临床, 2024, 44(8): 1094-1100.
[2]	李晋平, 刘汉卿, 杨全会. 大鼠严重腹腔感染后脾脏细胞周期的变化[J]. 基础医学与临床, 2024, 44(6): 828-832.
[3]	杨铠菲, 朱静格, 张洋洋, 赵俊果, 高雨悦, 胡焕焕, 姬国杰. 索拉菲尼诱导的细胞凋亡和自噬对HeLa细胞耐药性的影响[J]. 基础医学与临床, 2024, 44(4): 467-473.
[4]	李娜, 李涛, 杨冬梨, 姚媛. 和厚朴酚抑制人脂肪间充质干细胞增殖[J]. 基础医学与临床, 2024, 44(4): 483-488.
[5]	陈恩惠, 杨佳卉, 赵微, 解相宏, 郭艳芳, 刘晓军, 闫莉. Nutlin-3a通过抑制CIDEC的表达调控小鼠脂肪功能[J]. 基础医学与临床, 2024, 44(2): 154-158.
[6]	张梦瑶, 牛姝, 蔡静, 赵志刚, 周艳. miR-140-5p靶向HMGB1/IκB-α轴对糖尿病大鼠视网膜病变的影响[J]. 基础医学与临床, 2023, 43(4): 615-620.
[7]	金涛, 杨青山, 吴树金, 朱晓燕, 史宇悰, 牛建雄, 刘林. 内质网应激在骨关节炎中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 476-480.
[8]	张梦瑶, 牛姝, 蔡静, 张立香, 赵志刚. 丹参酮ⅡA减轻高糖诱导的小鼠足细胞系PMC-5凋亡和氧化应激反应[J]. 基础医学与临床, 2023, 43(2): 277-282.
[9]	王卉, 苏宪, 张赢赢, 褚战亚, 孙朝晖, 张金玲, 张倩倩. 异鼠李素减轻糖尿病视网膜病变大鼠视网膜细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 265-270.
[10]	刘婷婷, 韩超, 赵小玲, 孔为民. 二甲双胍抑制人宫颈鳞癌细胞系SiHa和CaSKi增殖及促进细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 283-288.
[11]	江宁, 郭钧, 刘铖, 周举. 莪术醇抑制人骨肉瘤细胞系的增殖和促凋亡[J]. 基础医学与临床, 2022, 42(8): 1200-1205.
[12]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[13]	董扬, 张芬, 李幸幸, 吴杰, 徐忠诚. 敲低miR-34c-5p抑制低氧诱导的大鼠骨髓间充质干细胞的凋亡[J]. 基础医学与临床, 2022, 42(11): 1690-1696.
[14]	雷家秀, 朱雅萍, 张雨. 依托咪酯上调miR-290-5p减轻LPS诱导的大鼠心肌细胞系H9C2损伤[J]. 基础医学与临床, 2021, 41(6): 848-853.
[15]	王伟, 赵四林, 范伏元, 金朝晖, 李妲, 符艳. 下调miR-199a-5p抑制脂多糖诱导的大鼠Ⅱ型肺泡上皮细胞系AECⅡ凋亡[J]. 基础医学与临床, 2021, 41(4): 521-527.